225 related articles for article (PubMed ID: 16505004)
1. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study.
Sylaja PN; Cote R; Buchan AM; Hill MD;
J Neurol Neurosurg Psychiatry; 2006 Jul; 77(7):826-9. PubMed ID: 16505004
[TBL] [Abstract][Full Text] [Related]
2. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.
Huang X; Cheripelli BK; Lloyd SM; Kalladka D; Moreton FC; Siddiqui A; Ford I; Muir KW
Lancet Neurol; 2015 Apr; 14(4):368-76. PubMed ID: 25726502
[TBL] [Abstract][Full Text] [Related]
3. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis.
Whiteley WN; Emberson J; Lees KR; Blackwell L; Albers G; Bluhmki E; Brott T; Cohen G; Davis S; Donnan G; Grotta J; Howard G; Kaste M; Koga M; von Kummer R; Lansberg MG; Lindley RI; Lyden P; Olivot JM; Parsons M; Toni D; Toyoda K; Wahlgren N; Wardlaw J; Del Zoppo GJ; Sandercock P; Hacke W; Baigent C;
Lancet Neurol; 2016 Aug; 15(9):925-933. PubMed ID: 27289487
[TBL] [Abstract][Full Text] [Related]
4. Influence of antiplatelet pre-treatment on the risk of intracranial haemorrhage in acute ischaemic stroke after intravenous thrombolysis.
Dorado L; Millán M; de la Ossa NP; Guerrero C; Gomis M; López-Cancio E; Ricciardi AC; Dávalos A
Eur J Neurol; 2010 Feb; 17(2):301-6. PubMed ID: 19912320
[TBL] [Abstract][Full Text] [Related]
5. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
Kono S; Deguchi K; Morimoto N; Kurata T; Yamashita T; Ikeda Y; Narai H; Manabe Y; Takao Y; Kawada S; Kashihara K; Takehisa Y; Inoue S; Kiriyama H; Abe K
J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Intravenous Low-Dose Alteplase in Relative Contraindication Patients with Acute Ischemic Stroke.
Ohta T; Okada K; Fukuda M; Masahira N; Matsuoka T; Tsuno T; Takemura M
J Stroke Cerebrovasc Dis; 2018 Jul; 27(7):1844-1851. PubMed ID: 29555402
[TBL] [Abstract][Full Text] [Related]
7. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.
Campbell BCV; Ma H; Ringleb PA; Parsons MW; Churilov L; Bendszus M; Levi CR; Hsu C; Kleinig TJ; Fatar M; Leys D; Molina C; Wijeratne T; Curtze S; Dewey HM; Barber PA; Butcher KS; De Silva DA; Bladin CF; Yassi N; Pfaff JAR; Sharma G; Bivard A; Desmond PM; Schwab S; Schellinger PD; Yan B; Mitchell PJ; Serena J; Toni D; Thijs V; Hacke W; Davis SM; Donnan GA;
Lancet; 2019 Jul; 394(10193):139-147. PubMed ID: 31128925
[TBL] [Abstract][Full Text] [Related]
8. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST).
Wahlgren N; Ahmed N; Eriksson N; Aichner F; Bluhmki E; Dávalos A; Erilä T; Ford GA; Grond M; Hacke W; Hennerici MG; Kaste M; Köhrmann M; Larrue V; Lees KR; Machnig T; Roine RO; Toni D; Vanhooren G;
Stroke; 2008 Dec; 39(12):3316-22. PubMed ID: 18927461
[TBL] [Abstract][Full Text] [Related]
9. Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with thrombolytic therapy: Paul Coverdell Acute Stroke Registry 2008-2012.
Tong X; George MG; Yang Q; Gillespie C
Int J Stroke; 2014 Aug; 9(6):728-34. PubMed ID: 24024962
[TBL] [Abstract][Full Text] [Related]
10. Safety of off-label stroke treatment with tissue plasminogen activator.
Kvistad CE; Logallo N; Thomassen L; Waje-Andreassen U; Brøgger J; Naess H
Acta Neurol Scand; 2013 Jul; 128(1):48-53. PubMed ID: 23311439
[TBL] [Abstract][Full Text] [Related]
11. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.
Anderson CS; Huang Y; Lindley RI; Chen X; Arima H; Chen G; Li Q; Billot L; Delcourt C; Bath PM; Broderick JP; Demchuk AM; Donnan GA; Durham AC; Lavados PM; Lee TH; Levi C; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Silva F; Song L; Thang NH; Wardlaw JM; Wang JG; Wang X; Woodward M; Chalmers J; Robinson TG;
Lancet; 2019 Mar; 393(10174):877-888. PubMed ID: 30739745
[TBL] [Abstract][Full Text] [Related]
12. Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW).
Rha JH; Shrivastava VP; Wang Y; Lee KE; Ahmed N; Bluhmki E; Hermansson K; Wahlgren N;
Int J Stroke; 2014 Oct; 9 Suppl A100():93-101. PubMed ID: 22988894
[TBL] [Abstract][Full Text] [Related]
13. Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study.
Aoki S; Hosomi N; Sueda Y; Kono T; Takamatsu K; Ohyama H; Torii T; Kitamura T; Nomura E; Noda K; Ohtsuki T; Matsumoto M;
J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2747-53. PubMed ID: 26360972
[TBL] [Abstract][Full Text] [Related]
14. Time to recanalization and risk of symptomatic intracerebral haemorrhage in patients treated with intravenous thrombolysis.
Dorado L; Millán M; Pérez de la Ossa N; Guerrero C; Gomis M; Aleu A; López-Cancio E; Cuadras P; Dávalos A
Eur J Neurol; 2012 Sep; 19(9):1251-5. PubMed ID: 22568604
[TBL] [Abstract][Full Text] [Related]
15. Rescue localized intra-arterial thrombolysis for hyperacute MCA ischemic stroke patients after early non-responsive intravenous tissue plasminogen activator therapy.
Kim DJ; Kim DI; Kim SH; Lee KY; Heo JH; Han SW
Neuroradiology; 2005 Aug; 47(8):616-21. PubMed ID: 15983773
[TBL] [Abstract][Full Text] [Related]
16. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
[TBL] [Abstract][Full Text] [Related]
17. The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
Flint AC; Gupta R; Smith WS; Kamel H; Faigeles BS; Cullen SP; Rao VA; Bath PM; Wahlgren N; Ahmed N; Donnan GA;
Int J Stroke; 2014 Aug; 9(6):705-10. PubMed ID: 25042855
[TBL] [Abstract][Full Text] [Related]
18. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ
Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898
[TBL] [Abstract][Full Text] [Related]
19. Predictors of symptomatic intracranial haemorrhage in patients with an ischaemic stroke with neurological deterioration after intravenous thrombolysis.
James B; Chang AD; McTaggart RA; Hemendinger M; Mac Grory B; Cutting SM; Burton TM; Reznik ME; Thompson B; Wendell L; Mahta A; Siket M; Madsen TE; Sheth KN; Nouh A; Furie KL; Jayaraman MV; Khatri P; Yaghi S
J Neurol Neurosurg Psychiatry; 2018 Aug; 89(8):866-869. PubMed ID: 29487169
[TBL] [Abstract][Full Text] [Related]
20. Off-label thrombolysis versus full adherence to the current European Alteplase license: impact on early clinical outcomes after acute ischemic stroke.
Cappellari M; Moretto G; Micheletti N; Donato F; Tomelleri G; Gulli G; Carletti M; Squintani GM; Zanoni T; Ottaviani S; Romito S; Tommasi G; Musso AM; Deotto L; Gambina G; Zimatore DS; Bovi P
J Thromb Thrombolysis; 2014 May; 37(4):549-56. PubMed ID: 23943338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
